Document is current

Article History

Received: 4 July 2019

Revised: 30 October 2019

Accepted: 15 November 2019

First Online: 16 December 2019

Ethics approval and consent to participate

: All patients who participated in the DOC-MEK study provided written informed consent, including consent to use of archival tissue samples and clinical data for exploratory research analysis. The protocol was approved by the NHS Oxfordshire A Research Ethics Committee. The study was conducted according to UK Clinical Trials Regulations and the ICH guidelines of Good Clinical Practice in accordance with the Declaration of Helsinki.

: Not applicable.

: The dataset used and analysed for this paper is available from the corresponding author on request.

: A.G. has consulted for and received honoraria from BMS and Novartis. R.B., D.R.H., A.S. and P.S. are employees of AstraZeneca. R.B. has shares in AstraZeneca. A.S. has received honoraria from Gilead, Roche, Janssen and Abbvie, and an unrestricted educational grant from Gilead and Janssen. M.R.M. has consulted for and received research funding from AstraZeneca, GlaxoSmithKline and Roche. V.M.M. has consulted for Boehringer Ingelheim.

: The DOC-MEK trial was supported by the collaboration between AstraZeneca and the UK National Cancer Research Network (Grant number: A12154), for which AstraZeneca provided partial funding. DOC-MEK was sponsored by the University of Oxford and was run by the Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford. This study was supported by funding from the Oxford NIHR Biomedical Research Centre to AS, MRM and VMM, and an Oxfordshire Health Services Research Committee grant to AG. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the United Kingdom’s Department of Health. FW and CT were supported by funding to the Preclinical Validation Laboratory from the Cancer Research UK Oxford Cancer Research Centre.